Table 3.
Concordance between ddPCR and plasma-sequencing analysis of pre-treatment plasma samples.
| Pta | Mutation for ddPCR analysis | Mutation present in sequencing of pre-treatment sample | MAF% detected by sequencing | Mean coverage of cfDNA sequencing | MAF% detected by ddPCR |
|---|---|---|---|---|---|
| pt101 | KRAS G12D | no | Not available | 112 | 1.7 |
| pt102 | TP53–221T < TTC | yes | 0.3 | 406 | 3.8 |
| pt103 | KRAS G12D | yes | 28 | 306 | 36 |
| pt104 | APC-507C > T | yes | 40 | 275 | 49 |
| pt105 | BRAF V600E | yes | 9 | 419 | 2.7 |
| pt107 | KRAS G12D | yes | 30 | 238 | 39 |
| pt109 | PARK2-214G > A | Not on panel | Not on panel | 211 | 17 |
| pt110 | KRAS G12C | yes | 17 | 152 | 79 |
| pt111 | KRAS G12V | no | Not available | 195 | 0.7 |
| pt112 | ERBB2-392A > G | yes | 4 | 327 | 7.4 |
| pt113 | TP53-003G > A | no | Not available | 310 | 0.8 |
| pt114 | Tp53-533G > A | yes | 13 | 253 | 1.7 |
| pt116 | KRAS G12A | yes | 33 | 310 | 36 |
| pt117 | KRAS G12V | no | Not available | 109 | 37 |
| pt118 | KRAS G13D | yes | 36 | 170 | 38 |
Targeted sequencing of pre-treatment plasma sample. For 17 out of 24 patients plasma DNA were available for targeted sequencing. NA means that no sample within two months of progression was available.
aNo mutated DNA in patients pt106 and pt108 were detected.